A Multiple Sclerosis Clinical Trial Collaboration

GeNeuro and Worldwide Clinical Trials collaborated on the development of a new, exciting molecule for the treatment of multiple sclerosis (MS). GeNeuro was founded in 2006 to work on endogenous retroviruses, with the mission of developing new drugs and treating patients with neurodegenerative and autoimmune disorders by neutralizing these causal factors. The company’s lead product is a monoclonal antibody targeting the protein pHERV-W Env of endogenous retroviral origin.